Novo Anticipates Q4 Soft Launch For Closely Watched Oral GLP-1 Agent Rybelsus In The US

 
• By Mandy Jackson

US CMO Todd Hobbs told Scrip the full launch will be in early 2020 as sales, manufacturing and reimbursement preparations for oral semaglutide continue based on the now-approved FDA label in type 2 diabetes.

Form close up, fountain pen and approved stamped on a document. Soft focus. - Image
The US FDA approved Rybelsus, the first oral GLP-1 agonist. • Source: Shutterstock

More from New Products

More from Scrip